A new antibiotic, tautomycin.

Cheng, Xing-Chun; Kihara, Tsuyoshi; Kusakabe, Hiroo; Magae, Junji; Kobayashi, Yumiko; Fang, Ren-Pin; Ni, Zher-Fu; SHENT, YIN-CHU; Ko, Keido; Yamaguchi, Isamu; Isono, Kiyoshi

doi:10.7164/antibiotics.40.907

Cited by 116 publications

(75 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To discover novel natural products that are normally expressed at a very low level, we have been performing a systematic isolation of secondary metabolites. As a result, we isolated verticilactam 4 from Streptomyces spiroverticillatus JC-8444, a tautomycin producer, 5 and 6-dimethylallylindole-3-carbaldehyde 6 from S. reveromyceticus SN-593, a reveromycin producer. 7 In addition, from S. reveromyceticus SN-593, we detected metabolites showing UV spectra similar to furaquinocin (FQ), but different mass from the reported FQs.…”

Section: Introductionmentioning

confidence: 99%

Furaquinocins I and J: novel polyketide isoprenoid hybrid compounds from Streptomyces reveromyceticus SN-593

et al. 2011

View full text Add to dashboard Cite

Two novel furaquinocin (FQ) analogues, I (1) and J (2), were isolated from Streptomyces reveromyceticus SN-593 strain NRM2. Their structures were elucidated by MS and NMR analyses. Similar to the previously described FQ D (3), both 1 and 2 possessed a dihydrofuran ring fused to a polyketide naphthoquinone skeleton. The main difference between 1, 2 and 3 was the type of residue attached to C-13; these were a carboxyl, a carboxamide and a methyl residue, respectively. INTRODUCTIONThe majority of bioactive compounds used as drugs and bioprobes originally derive from the secondary metabolites of microorganisms. Genome sequence analyses have shown that the number of bioactive compounds isolated from Streptomyces spp. is much lower than the number of gene clusters harbored by each species. [1][2][3] This indicates that the majority of gene clusters are either not expressed, or are only minimally expressed, under standard laboratory conditions. To discover novel natural products that are normally expressed at a very low level, we have been performing a systematic isolation of secondary metabolites. As a result, we isolated verticilactam 4 from Streptomyces spiroverticillatus JC-8444, a tautomycin producer, 5 and 6-dimethylallylindole-3-carbaldehyde 6 from S. reveromyceticus SN-593, a reveromycin producer. 7 In addition, from S. reveromyceticus SN-593, we detected metabolites showing UV spectra similar to furaquinocin (FQ), but different mass from the reported FQs. Consistent with the finding, we could annotate an FQ biosynthetic gene cluster from the genome draft sequence. However, with the quantity produced by wild type strain, it was not possible to isolate and determine the structure. So, in order to improve the production of novel FQ derivatives, we performed the expression of pathway-specific regulatory genes associated with the FQ biosynthetic gene cluster. Activation of pathwayspecific positive regulatory gene is commonly used for augmentation of secondary metabolites in Streptomyces. [8][9][10] FQs, originally isolated from the culture broth of Streptomyces sp. 11 have cytocidal activities without antibacterial activity. So far, eight analogues of these polyketide isoprenoid hybrid compounds (Figure 1) [11][12][13] and their gene cluster 14 have been identified.

show abstract

Section: Introductionmentioning

confidence: 99%

Furaquinocins I and J: novel polyketide isoprenoid hybrid compounds from Streptomyces reveromyceticus SN-593

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Thus, we constructed a microbial metabolite fraction library by systematic separation with a spectral database, based on photodiode-array detector attached LC/MS analysis to discover structurally unique metabolites efficiently and rapidly. We discovered and isolated verticilactam 6 from S. spiroveticillatus JC-8444, a tautomycin producer, [7][8][9] and the new fraquinocins I and J 10 and 6-dimethylalylindole-3-carbaldehyde 11 from S. reveromyceticus SN-593, a reveromycin producer 12 by our methodology constructing the fraction library. Also, Bugni et al 13 reported a marine natural products library by HPLC-MS fractionation for rapid drug discovery.…”

Section: Introductionmentioning

confidence: 99%

Spirotoamides A and B, novel 6,6-spiroacetal polyketides isolated from a microbial metabolite fraction library

et al. 2011

View full text Add to dashboard Cite

Two new 6,6-spiroacetal polyketides, spirotoamides A (1) and B (2), were isolated from a microbial metabolite fraction library of Streptomyces griseochromogenes JC82-1223 by screening of structurally unique compounds based on a search of spectral database. The fraction library was constructed using a systematic separation method to efficiently discover new metabolites from microbial sources such as actinomycetes and fungi. The structures of 1 and 2 were elucidated by 2D-NMR and mass spectrometric measurements. They belong to a class of polyketides, and contain a 6,6-spiroacetal core structure and a carboxamide group. The biosynthetic pathway of 1 and 2 is discussed in the text. Keywords: fraction library; microbial metabolite; spiroacetal polyketide; Streptomyces griseochromogenes; structure elucidation INTRODUCTION Microorganisms, such as actinomycetes and fungi, have a tremendous capacity to produce structurally diverse metabolites 1 with disparate activities, rendering them a significant source of pharmaceutical leads and therapeutic agents. 2,3 They are also used as potential bioprobes for chemical biology studies. 4,5 Many secondary metabolites have been reported, but not all have been isolated, nor have their wide-ranging physicochemical properties and low abundance been examined with regard to their potentially useful activities. Thus, we constructed a microbial metabolite fraction library by systematic separation with a spectral database, based on photodiode-array detector attached LC/MS analysis to discover structurally unique metabolites efficiently and rapidly. We discovered and isolated verticilactam 6 from S. spiroveticillatus JC-8444, a tautomycin producer, 7-9 and the new fraquinocins I and J 10 and 6-dimethylalylindole-3-carbaldehyde 11 from S. reveromyceticus SN-593, a reveromycin producer 12 by our methodology constructing the fraction library. Also, Bugni et al. 13 reported a marine natural products library by HPLC-MS fractionation for rapid drug discovery. These reports have demonstrated the advantage of fraction libraries in isolating and investigating the activities of natural products.Our microbial fraction library was developed on basic chromatographic techniques, comprizing two-step separation by middlepressure liquid chromatography (MPLC) and C 18 -HPLC, yielding 300-400 fractions from a single microbial strain with reproducibility. In addition to many known compounds, the fractions, which contain unidentified minor components, might contain valuable compounds

show abstract

“…Staurosporine and tautomycin were isolated from culture broth of an unidentified Actinomyces and Streptomyces spiroverticillatus. 2) Other reagents were purchased from commercial suppliers.…”

Section: Methodsmentioning

confidence: 99%

Screening for Specific Inhibitors of Phagocytosis of Thioglycollate-elicited Macrophages

Magae

Nagi

Takaku

et al. 1994

Bioscience, Biotechnology, and Biochemistry

Self Cite

View full text Add to dashboard Cite

A new antibiotic, tautomycin.

Cited by 116 publications

References 4 publications

Furaquinocins I and J: novel polyketide isoprenoid hybrid compounds from Streptomyces reveromyceticus SN-593

Furaquinocins I and J: novel polyketide isoprenoid hybrid compounds from Streptomyces reveromyceticus SN-593

Spirotoamides A and B, novel 6,6-spiroacetal polyketides isolated from a microbial metabolite fraction library

Screening for Specific Inhibitors of Phagocytosis of Thioglycollate-elicited Macrophages

Contact Info

Product

Resources

About